Horizon Technology Finance Management
Horizon Technology Finance Management, LLC is a venture lending firm that specializes in providing structured debt products, including senior and subordinated venture loans, secured working capital loans, and equipment loans, to development-stage companies primarily in the technology and life sciences sectors. Founded in 2003 and headquartered in Farmington, Connecticut, with additional offices in Pleasanton, California, and Reston, Virginia, Horizon focuses on investments in areas such as cloud computing, biotechnology, and alternative energy. The firm targets companies in the Mid-Atlantic and Western regions of the United States, offering loans ranging from $1 million to $25 million, with repayment terms of up to 48 months. With a team that has collectively originated over $5 billion in venture loans, Horizon aims to support innovative companies by providing essential capital to fuel their growth.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in New Jersey
Onkos Surgical
Debt Financing in 2025
Onkos Surgical Inc. is a privately-held company based in Parsippany, New Jersey, focused on providing advanced technologies and solutions for surgical oncologists. Founded in 2014, Onkos Surgical is dedicated to transforming the treatment of musculoskeletal cancers and complex orthopedic conditions. The company offers innovative products such as GenVie, a magnesium bone scaffolding technology, and the ELEOS Proximal Tibia, a 3D printed limb salvage replacement. By leveraging cutting-edge techniques in virtual surgical planning, 3D modeling and printing, and personalized surgical planning, Onkos Surgical aims to enhance patient outcomes and improve the overall experience for both patients and healthcare professionals.
PDS Biotechnology
Post in 2022
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company based in North Brunswick, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. Founded in 2005, the company aims to prevent and treat various cancers, including cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, and vulvar cancers. PDS Biotechnology's product pipeline includes PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a series of immunotherapy products for non-viral cancers. The company's proprietary Versamune platform technology is designed to activate and direct the human immune system to effectively target and attack cancer cells, supporting its commitment to innovative cancer treatment solutions.
Palatin Technologies
Post in 2014
Palatin Technologies is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics. Its work centers on modulating melanocortin receptor and natriuretic peptide receptor systems to treat diseases with unmet medical needs and commercial potential. The lead product is Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The company is developing several additional candidates, including PL8177 (oral and systemic) targeting inflammatory and ocular conditions, such as non-infectious uveitis and dry eye disease; PL9643, a multi-receptor melanocortin agonist for ocular inflammation; PL3994, an NPR-A agonist for cardiovascular indications; and PL5028, a dual NPR-A/NPR-C agonist for cardiovascular and fibrotic diseases. It also explores indications in obesity, erectile dysfunction, pulmonary diseases, and other inflammatory conditions, leveraging melanocortin pathways to modulate inflammation and healing.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.